David A. Siegel Enlivex Therapeutics Ltd. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020
SELL
$4.64 - $5.94 $46,864 - $59,994
-10,100 Closed
0 $0
Q2 2020

Aug 14, 2020
BUY
$4.4 - $6.4 $44,440 - $64,640
10,100 New
10,100 $51,000

Others Institutions Holding ENLV

# of Institutions
24
Shares Held
2.58M
Call Options Held
20.8K
Put Options Held
3K
View Full List

About Enlivex Therapeutics Ltd.

ENLV Quotes by TradingView
  • Ticker ENLV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,403,200
  • Market Cap $16.2M
  • Description
  • Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...
More about ENLV
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email